ethyl 2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetate | 142929-50-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetate
• 英文别名: Ethyl {2-[(tert-butoxycarbonyl)amino]ethoxy}acetate；ethyl 2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]acetate
• CAS: 142929-50-8
• 化学式: C₁₁H₂₁NO₅
• mdl: MFCD24393521
• 分子量: 247.291
• InChiKey: JGDJDRSVDKZPGV-UHFFFAOYSA-N

物化性质

• 沸点：
  351.7±22.0 °C(Predicted)
• 密度：
  1.064±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetate 在 lithium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.5h， 以74%的产率得到Boc-5-氨基-3-氧杂戊酸
  参考文献：
  名称：

  受N保护的羧基烷基醚胺的简明合成

  摘要：

  连接生物分子的水溶性聚（乙二醇1）（PEG）接头由于其生物相容性、两亲性、低免疫原性和毒性而在药物化学中得到广泛应用。'-9 短双功能乙二醇接头提供了 PEG 的理想特性，是极具吸引力的材料用于生物共轭。1°-13 我们在本文中提出了一系列短双功能接头的简明合成，即 N-保护的羧烷基醚胺（图 1）。先前为制备这些化合物所做的努力仅限于多步骤序列或特定制备，即 RNH k0k 不适用于制备各种 N-保护的羧烷基醚胺。I4I6 我们的方法设想用溴乙酸烷基酯对 N-保护的氨基醇 la-f 进行 0-烷基化，然后进行酯水解，得到所需的化合物（方案 1）。在第一步中缺乏化学选择性去质子化将导致由 N-烷基化、O-烷基化和/或两者产生的产物的混合物。温度和反离子对烷基化CO2H影响的简要研究

  DOI：

  10.1080/00304940209356773
• 作为产物：
  描述：

  3-氧代吗啉-4-羧酸叔丁酯 在 lithium hydroxide 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.0h， 生成 ethyl 2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetate
  参考文献：
  名称：

  Analogs of the .delta. opioid receptor selective cyclic peptide [cyclic][2-D-penicillamine,5-D-penicillamine]-enkephalin: 2',6'-dimethyltyrosine and Gly3-Phe4 amide bond isostere substitutions

  摘要：

  In order to develop systemically-active opioid peptides, the delta-selective, opioid pentapeptide [D-Pen2,D-Pen5]-enkephalin (DPDPE) was modified by esterification and by substitution of 2,6-dimethyltyrosine for tyrosine to yield 4. Compound 4 was on the order of 8- and 800-fold more active than DPDPE in both delta and mu-opioid radioligand binding assays, respectively, in rat neural membrane suspensions. Compound 4 was considerably more potent than DPDPE at inhibiting contractions of electrically-stimulated mouse vas deferens in vitro, and this effect was very sensitive to naltrindole, a delta-selective opioid antagonist. These observations can be taken as indication that 4 exerts its effects through delta-opioid receptors. This interpretation is supported by the finding that the EC50 value of 4 derived in the smooth muscle assay is very similar to that derived in NG108-15 neuroblastoma cells, a preparation devoid of mu-receptors. Unlike DPDPE, 4 exhibited significant, naloxone-sensitive, antinociceptive activity when administered systemically, as measured by inhibition of phenylbenzquinone-induced stretching in mice (ED50 = 2.1 mg/kg). Compound 4 also displayed significant antinociceptive activity following systemic administration as measured by its action in mice to increase latencies for tail withdrawal from radiant heat (ED50 = 50 mg/kg). Compound 4 did not produce morphine-like discriminative stimulus effects in rats trained to discriminate 3.0 mg/kg morphine from vehicle at doses ranging from 30 to 120 mg/kg. This observation can be interpreted as indication that within this dosage range there is an absence of morphine-like subjective effects. Physical dependence, however, could be induced in mice at higher doses of 4 under a progressively-graded, 4-day dose regimen. Congeners of 4 with amide bond surrogates for the Gly-Phe amide bond (oxymethylene, trans-double bond, and bismethylene isosteres) in the cyclic core of DPDPE were prepared in an attempt to increase the antinociceptive activity of 4. While some of the were active in the in vitro assays, they did not display significant antinociceptive activity following systemic administration. The preparation of all the compounds was accomplished by solution-phase methods. The which might underlie the biological and systemic activity of 4 are discussed.

  DOI：

  10.1021/jm00094a002

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE ET COMPOSÉS CORRESPONDANTS UTILISÉS EN TANQUE QUE AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) UTILISÉS POUR LE TRAITEMENT DE, P.EX., DE L'ANGIOGENÈSE IMPLIQUÉE OU DE TROUBLES INFLAMMATOIRES
  申请人：IKENA ONCOLOGY INC

  公开号：WO2021127302A1

  公开（公告）日：2021-06-24

  2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).

  2-(1H-吲哚-3-甲酰基)-噻唑-4-羧酰胺衍生物及相应的咪唑、噁唑和噻吩衍生物以及相关化合物作为芳香烃受体（AHR）激动剂，用于治疗涉及血管生成的疾病，例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症，或炎症性疾病。本说明书揭示了示例化合物的合成和表征以及其药理数据（例如第27至32页和59至219页；示例1至8；化合物1-1至1-97；表1-a、2和3）。
• Synthesis and binding properties of guanidinium biscarboxylates
  作者：Andreas Späth、Janina Gonschor、Burkhard König

  DOI：10.1007/s00706-011-0660-x

  日期：2011.12

  AbstractThe ammonium ion binding site of the enzyme glutaminase HisF inspired us to design guanidinium biscarboxylates as potential self-organized ionophores in molecular recognition. The syntheses of the title compounds based on aliphatic and aromatic building blocks, along with a general method for the preparation of δ-aminoethoxyacetic acids, are presented in this work. Investigation of the binding

  摘要谷氨酰胺酶HisF的铵离子结合位点启发我们设计双羧酸胍盐作为分子识别中潜在的自组织离子载体。这项工作介绍了基于脂肪族和芳香族结构单元的标题化合物的合成，以及制备δ-氨基乙氧基乙酸的一般方法。对标题化合物在二甲亚砜（DMSO）和甲醇溶液中的结合性能的研究表明，没有铵离子亲和力，但胍基部分与乙酸根离子相互作用。 图形概要
• INHIBITORS OF SOLUBLE ADENYLYL CYCLASE
  申请人：CORNELL UNIVERSITY

  公开号：US20200157084A1

  公开（公告）日：2020-05-21

  Provided are 6-amino substituted 2,6-diamino-4-choropyrimidine compounds which are specific inhibitors of soluble adenylyl cyclase. The compounds can be formulated with pharmaceutical carriers and used for reducing cyclic AMP levels. The compositions can be used for treatment of various conditions including ocular hypotony.

  提供了6-氨基取代的2,6-二氨基-4-氯嘧啶化合物，这些化合物是可溶性腺苷酸环化酶的特异性抑制剂。这些化合物可以与药用载体配制，并用于降低环磷酸腺苷水平。这些组合物可用于治疗包括眼压低等各种疾病。
• HMOX1 inducers
  申请人：Mitobridge Inc.

  公开号：US10766888B1

  公开（公告）日：2020-09-08

  The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

  本发明涉及结构（I）的化合物作为血红素氧合酶1（HMOX 1）诱导剂。本发明还涉及一种控制哺乳动物体内血红素氧合酶1的活性或数量，或活性和数量的方法。这里提供了变量的定义。